Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Auro LaboratoriesBOM:530233 +1.16%57 Pretax Margin % is 14.80% as of Mar. 2026, which is 19% above its 10-year median of 12.47. GuruFocus rates BOM:530233 with a GF Score™ of 57/100 and a GF Value™ of ₹152.37 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 960 Drug Manufacturers companies, Auro Laboratories ranks better than 71.87% on this metric.
The historical rank and industry rank for Auro Laboratories's Pretax Margin % or its related term are showing as below:
BOM:530233'
s Pretax Margin % Range Over the Past 10 Years
Min: 6.59 Med: 12.47 Max: 19.85
Current: 15.59
BOM:530233's Pretax Margin % is ranked better than 71.87% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.045
vs BOM:530233: 15.59
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Auro Laboratories Pretax Margin % Related Terms
Auro Laboratories Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Auro Laboratories's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Auro Laboratories's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Auro Laboratories Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Auro Laboratories's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Auro Laboratories's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Auro Laboratories (BOM:530233) has a Pretax Margin % of 14.80% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Auro Laboratories and its competitors. This is 19% above median its historical median of 12.47. Over the past decade, Auro Laboratories' Pretax Margin % has ranged from 6.59 to 19.85. According to the industry distribution chart, Auro Laboratories ranks #270 out of 960 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is Auro Laboratories' Pretax Margin % too high?
Auro Laboratories' current Pretax Margin % of 14.80% is 19% above median its 10-year median of 12.47. Over the past 10 years, this metric has ranged from a low of 6.59 to a high of 19.85. The Drug Manufacturers industry median Pretax Margin % is 7.05. Auro Laboratories' value of 14.80% is 110.1% above this industry median. Based on the distribution chart, Auro Laboratories ranks #270 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Auro Laboratories has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Auro Laboratories' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Auro Laboratories ranks #270 out of 960 companies for Pretax Margin %. This puts Auro Laboratories in the upper half of its industry. The industry median Pretax Margin % is 7.05. Auro Laboratories' value of 14.80% is 110.1% above this benchmark. Historically, Auro Laboratories' own Pretax Margin % has ranged from 6.59 to 19.85 over the past decade. While the company's 10-year median is 12.47 vs. the industry median of 7.05, Auro Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.05, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Auro Laboratories's current Pretax Margin % of 14.80% is 110.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Auro Laboratories and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Auro Laboratories's current Pretax Margin % is 14.80%, which is 19% above median its own 10-year median of 12.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Auro Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Auro Laboratories (BOM:530233) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹152.37, compared to a current price of ₹234.75 — trading 54.1% above its estimated fair value. The current Pretax Margin % is 14.80%, which is 19% above median its 10-year median of 12.47 and 110.1% above the Drug Manufacturers industry median of 7.05. Auro Laboratories' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Auro Laboratories (BOM:530233), the current Pretax Margin % is 14.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Auro Laboratories (BOM:530233) Overvalued in 2026?
Based on GuruFocus' analysis, Auro Laboratories stock appears to be overvalued.
The current stock price of ₹234.75 is trading 54.1% above its estimated GF Value™ of ₹152.37.
GuruFocus considers Auro Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:530233:
Pretax Margin %: 14.80% (19% above median its 10-year median of 12.47)
GF Value™: ₹152.37 vs. price of ₹234.75 (54.1% above fair value)
Industry Position: 110.1% above the Drug Manufacturers median (#270 of 960)
No single metric tells the full story. See the BOM:530233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Auro Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and selling of pharmaceutical products like Metformin Hydrochloride and Glibenclamide. The pharmaceutical products range offered by the company are anti-diabetic, muscle relaxant, diuretic, iron deficiency anti-fungal, anti-ulcer, iodine supplement, anti-malaria, antacids, anti-inflammatory, specialty chemicals, and others. The company sells its products in India and also exports it to international countries.
57GF Score
Get the complete analysis for BOM:530233
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530233 has been successfully added to your 
